306 related articles for article (PubMed ID: 28844082)
21. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
22. The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
Cook MR; Karp JE; Lai C
EJHaem; 2022 Feb; 3(1):301-313. PubMed ID: 35846202
[TBL] [Abstract][Full Text] [Related]
23. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
GenoMed4All consortium
Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
25. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
26. Have we reached a molecular era in myelodysplastic syndromes?
Voso MT; Gurnari C
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):418-427. PubMed ID: 34889424
[TBL] [Abstract][Full Text] [Related]
27. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
28. [Current diagnosis and treatment for myelodysplastc syndromes].
Hata T
Rinsho Ketsueki; 2017; 58(4):373-380. PubMed ID: 28484169
[TBL] [Abstract][Full Text] [Related]
29. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.
Haider M; Duncavage EJ; Afaneh KF; Bejar R; List AF
Am Soc Clin Oncol Educ Book; 2017; 37():480-494. PubMed ID: 28561687
[TBL] [Abstract][Full Text] [Related]
30. [Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review].
Xu YY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):285-9. PubMed ID: 26913438
[TBL] [Abstract][Full Text] [Related]
31. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
32. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.
Lee EJ; Podoltsev N; Gore SD; Zeidan AM
Blood Rev; 2016 Jan; 30(1):1-10. PubMed ID: 26119927
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
34. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
35. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Nazha A; Narkhede M; Radivoyevitch T; Seastone DJ; Patel BJ; Gerds AT; Mukherjee S; Kalaycio M; Advani A; Przychodzen B; Carraway HE; Maciejewski JP; Sekeres MA
Leukemia; 2016 Nov; 30(11):2214-2220. PubMed ID: 27311933
[TBL] [Abstract][Full Text] [Related]
36. [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes].
Huang HJ; Li B; Qin TJ; Xu ZF; Hu NB; Pan LJ; Qu SQ; Liu D; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):723-730. PubMed ID: 33113603
[No Abstract] [Full Text] [Related]
37. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.
Bersanelli M; Travaglino E; Meggendorfer M; Matteuzzi T; Sala C; Mosca E; Chiereghin C; Di Nanni N; Gnocchi M; Zampini M; Rossi M; Maggioni G; Termanini A; Angelucci E; Bernardi M; Borin L; Bruno B; Bonifazi F; Santini V; Bacigalupo A; Voso MT; Oliva E; Riva M; Ubezio M; Morabito L; Campagna A; Saitta C; Savevski V; Giampieri E; Remondini D; Passamonti F; Ciceri F; Bolli N; Rambaldi A; Kern W; Kordasti S; Sole F; Palomo L; Sanz G; Santoro A; Platzbecker U; Fenaux P; Milanesi L; Haferlach T; Castellani G; Della Porta MG
J Clin Oncol; 2021 Apr; 39(11):1223-1233. PubMed ID: 33539200
[TBL] [Abstract][Full Text] [Related]
38. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
[TBL] [Abstract][Full Text] [Related]
39. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
40. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
Xie Z; Chen EC; Stahl M; Zeidan AM
Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
